Expression of Glutaminase is Upregulated in Colorectal Cancer and of Clinical Significance

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2014 Apr 4

PMID 24696726

Citations 53

Authors

Fang Huang

Qiuyue Zhang

Hong Ma

Qing Lv

Tao Zhang

Affiliations

Soon will be listed here.

Abstract

Cancer cells remodel their metabolic programmes to meet the requirements of rapid proliferation. Glutaminase (GLS1) is a mitochondrial enzyme that converts glutamine to glutamate. Our aim was to investigate, for the first time, GLS1 protein expression in colorectal cancer and to evaluate its clinical significance. Immunohistochemical analysis was performed on tissue microarrays containing pairs of cancer and adjacent normal tissues from colorectal cancer patients (n=257). The expression of GLS1 protein in normal colonic tissues and colorectal cancer was measured by western blotting. Proliferation and cell death were evaluated in colorectal cancer cell lines after GLS1 inhibitor treatment. Compared with normal tissues (18.15%), we observed that the expression of GLS1 increased significantly in colorectal cancer (80.24%; P<0.0001) by immunohistochemical analysis, and the elevation of GLS1 protein expression levels in fresh colorectal cancer samples versus normal colonic tissues were also observed by western blotting. Furthermore, GLS1 expression levels were significantly associated with deeper tumour infiltration (P=0.0002), and the pathological pattern of tubular adenocarcinoma (p=0.0008). In addition, treatment with the GLS1 inhibitor suppressed proliferation and induced apoptosis in HT29 and SW480 cell lines. These results suggest that the expression of GLS1 is upregulated and correlates with clinicopathological factors in colorectal cancer. GLS1 exhibits functional importance in colon cancer tumorigenesis. Moreover, GLS1 may serve as a target for colorectal cancer therapy.

Citing Articles

Tumor Metabolic Reprogramming and Ferroptosis: The Impact of Glucose, Protein, and Lipid Metabolism.

Zhu K, Cai Y, Lan L, Luo N Int J Mol Sci. 2025; 25(24.

PMID: 39769177 PMC: 11676715. DOI: 10.3390/ijms252413413.

Mitochondrial Proteins as Metabolic Biomarkers and Sites for Therapeutic Intervention in Primary and Metastatic Cancers.

Robledo-Cadena D, Pacheco-Velazquez S, Vargas-Navarro J, Padilla-Flores J, Moreno-Sanchez R, Rodriguez-Enriquez S Mini Rev Med Chem. 2024; 24(12):1187-1202.

PMID: 39004839 DOI: 10.2174/0113895575254320231030051124.

Glutaminase - A potential target for cancer treatment.

Anthony J, Varalakshmi S, Sekar A, Devarajan N, Janakiraman B, Peramaiyan R Biomedicine (Taipei). 2024; 14(2):29-37.

PMID: 38939098 PMC: 11204126. DOI: 10.37796/2211-8039.1445.

CircCOL1A1 promotes proliferation, migration, and invasion of colorectal cancer (CRC) cells and glutamine metabolism through GLS1 up-regulation by sponging miR-214-3p.

Liu J, Zhang X, Yang M, Zhang X J Cancer Res Clin Oncol. 2024; 150(4):211.

PMID: 38662258 PMC: 11045592. DOI: 10.1007/s00432-024-05736-z.

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment.

Li X, Peng X, Li Y, Wei S, He G, Liu J Cell Commun Signal. 2024; 22(1):12.

PMID: 38172980 PMC: 10763057. DOI: 10.1186/s12964-023-01449-x.

References

DeBerardinis R, Cheng T . Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2009; 29(3):313-24. PMC: 2809806. DOI: 10.1038/onc.2009.358. View

Reitzer L, Wice B, Kennell D . Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979; 254(8):2669-76. View

Lobo C, Ruiz-Bellido M, Aledo J, Marquez J, Nunez de Castro I, Alonso F . Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J. 2000; 348 Pt 2:257-61. PMC: 1221061. View

Knox W, MORRIS H . Glutaminase activities and growth rates of rat hepatomas. Cancer Res. 1969; 29(6):1195-9. View

Segura J, Ruiz-Bellido M, Arenas M, Lobo C, Marquez J, Alonso F . Ehrlich ascites tumor cells expressing anti-sense glutaminase mRNA lose their capacity to evade the mouse immune system. Int J Cancer. 2001; 91(3):379-84. DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1046>3.3.co;2-c. View

Rhoads J, Argenzio R, Chen W, Rippe R, Westwick J, Cox A . L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am J Physiol. 1997; 272(5 Pt 1):G943-53. DOI: 10.1152/ajpgi.1997.272.5.G943. View

Qu W, Zha Z, Ploessl K, Lieberman B, Zhu L, Wise D . Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors. J Am Chem Soc. 2010; 133(4):1122-33. DOI: 10.1021/ja109203d. View

Kovacevic Z, MORRIS H . The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 1972; 32(2):326-33. View

Martin-Rufian M, Segura J, Lobo C, Mates J, Marquez J, Alonso F . Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display. Cancer Biol Ther. 2005; 5(1):54-8. DOI: 10.4161/cbt.5.1.2238. View

10.

Gao P, Tchernyshyov I, Chang T, Lee Y, Kita K, Ochi T . c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009; 458(7239):762-5. PMC: 2729443. DOI: 10.1038/nature07823. View

11.

Matsuno T, Goto I . Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res. 1992; 52(5):1192-4. View

12.

Wang J, Erickson J, Fuji R, Ramachandran S, Gao P, Dinavahi R . Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18(3):207-19. PMC: 3078749. DOI: 10.1016/j.ccr.2010.08.009. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Martin M, Beauvoit B, Voisin P, Canioni P, Guerin B, Rigoulet M . Energetic and morphological plasticity of C6 glioma cells grown on 3-D support; effect of transient glutamine deprivation. J Bioenerg Biomembr. 1999; 30(6):565-78. DOI: 10.1023/a:1020584517588. View

15.

Lacey J, Wilmore D . Is glutamine a conditionally essential amino acid?. Nutr Rev. 1990; 48(8):297-309. DOI: 10.1111/j.1753-4887.1990.tb02967.x. View

16.

Turner A, McGivan J . Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J. 2002; 370(Pt 2):403-8. PMC: 1223172. DOI: 10.1042/BJ20021360. View

17.

Lieberman B, Ploessl K, Wang L, Qu W, Zha Z, Wise D . PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med. 2011; 52(12):1947-55. DOI: 10.2967/jnumed.111.093815. View

18.

Matsuno T, Hirai H . Glutamine synthetase and glutaminase activities in various hepatoma cells. Biochem Int. 1989; 19(2):219-25. View

19.

Perez-Gomez C, Campos-Sandoval J, Alonso F, Segura J, Manzanares E, Ruiz-Sanchez P . Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J. 2004; 386(Pt 3):535-42. PMC: 1134872. DOI: 10.1042/BJ20040996. View

20.

Wise D, Thompson C . Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35(8):427-33. PMC: 2917518. DOI: 10.1016/j.tibs.2010.05.003. View